Background
Steven Appleget sought compensation under the National Vaccine Injury Compensation Program, alleging that an influenza vaccination caused Guillain-Barré syndrome. The special master had already ruled in Appleget’s favor on entitlement, leaving the amount of damages for pain and suffering as the disputed issue.
Appleget experienced lower-extremity paresthesias, weakness, an unsteady gait, reduced reflexes, and decreased sensation. He was hospitalized for four days, received five rounds of intravenous immunoglobulin, and was discharged able to walk without assistance and authorized to return to work immediately. His condition steadily improved, although gait, balance, fatigue, weakness, and other residual symptoms persisted during follow-up care and physical therapy.
Appleget requested $170,000 for past pain and suffering. The government argued for an award below that amount, characterizing his illness and treatment as comparatively mild and limited, but it did not propose a specific figure.
The Court’s Holding
Chief Special Master Corcoran awarded Appleget $145,000 in actual pain-and-suffering damages. Applying the Vaccine Act’s framework, the special master focused on Appleget’s awareness of the injury, its severity, and the duration of his suffering, while also considering awards in other reasoned Guillain-Barré decisions.
The special master characterized Appleget’s condition as a moderate case of Guillain-Barré syndrome with a conservative and relatively limited treatment course, a good prognosis, and no inpatient rehabilitation. Although Appleget did not establish the unusually traumatic course or extensive rehabilitation that supported higher awards in several cited cases, his active treatment extended nearly two years and the record documented continuing residual effects.
The special master rejected the government’s principal comparison to a $92,500 award as an outlier and found Appleget’s experience more comparable to recent moderate Guillain-Barré cases awarding approximately $135,000 to $145,000. The resulting $145,000 lump-sum award represented all damages available to Appleget under Section 15(a) of the Vaccine Act.
Key Takeaways
- A moderate Guillain-Barré case involving a short hospitalization, IVIG treatment, limited outpatient therapy, and lingering residual symptoms supported a $145,000 pain-and-suffering award.
- Prior reasoned decisions may guide Vaccine Act damages, but the claimant’s individual severity, treatment, recovery, and duration of suffering remain the most important considerations.
- A party challenging a requested damages amount is more helpful to the decision-maker when it proposes a specific alternative and supports it with genuinely comparable cases.
Why It Matters
The decision provides a current benchmark for valuing pain and suffering in a moderate Guillain-Barré claim that required hospitalization and IVIG but not inpatient rehabilitation or assisted ambulation at discharge. It also illustrates that a relatively strong early recovery does not preclude a substantial award when residual problems and medical supervision continue over an extended period.
For Vaccine Program practitioners, the ruling underscores the importance of comparisons grounded in reasoned decisions with similar treatment intensity and recovery trajectories, rather than relying principally on unusually low or factually dissimilar awards.